BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Premkumar M, Dhiman RK. Direct-Acting Antiviral Agents for HCV Infection. J Clin Exp Hepatol 2018;8:1-2. [PMID: 29743789 DOI: 10.1016/j.jceh.2018.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z. Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatol Int 2018;12:126-32. [PMID: 29637511 DOI: 10.1007/s12072-018-9856-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
3 Gandjour A. Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results. PLoS One 2020;15:e0236543. [PMID: 33006987 DOI: 10.1371/journal.pone.0236543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Urbanowicz A, Zagożdżon R, Ciszek M. Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy. Arch Immunol Ther Exp (Warsz) 2019;67:79-88. [PMID: 30443787 DOI: 10.1007/s00005-018-0532-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
6 Crismale JF, Ahmad J. Expanding treatment for hepatitis C in Canada. CMAJ 2018;190:E667-8. [PMID: 29866891 DOI: 10.1503/cmaj.170931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kivimets K, Uusküla A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis 2018;18:339. [PMID: 30031373 DOI: 10.1186/s12879-018-3242-2] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Moon AM, Green PK, Rockey DC, Berry K, Ioannou GN. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther 2020;51:364-73. [PMID: 31773763 DOI: 10.1111/apt.15586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
10 Doyle OM, Leavitt N, Rigg JA. Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data.Sci Rep. 2020;10:10521. [PMID: 32601354 DOI: 10.1038/s41598-020-67013-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhou B, Cai GFF, Lv HKK, Xu SFF, Wang ZTT, Jiang ZGG, Hu CGG, Chen YDD. Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Users-Findings from a Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2019;16:E2345. [PMID: 31269774 DOI: 10.3390/ijerph16132345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Margusino-Framiñán L, Cid-Silva P, Giménez-Arufe V, Mondelo-García C, Fernández-Oliveira C, Mena-de-Cea Á, Martín-Herranz I, Castro-Iglesias Á. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. Eur J Hosp Pharm 2021;28:16-21. [PMID: 33355279 DOI: 10.1136/ejhpharm-2019-001889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Piedade J, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves Ú, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep 2021;11:11681. [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1] [Reference Citation Analysis]
14 Nappi A, Perrella A, Rinaldi L, Izzi A, Punzi R, Adinolfi LE, Sbeglia C, Bellopede P, Maddaloni A, Papa N, Spatarella M. Late HCC onset after DAAs therapy in patients with SVR: a type D ADR that requires a longer follow-up? Eur J Hosp Pharm 2019;26:243-4. [PMID: 31338185 DOI: 10.1136/ejhpharm-2019-001975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States: A National, Retrospective Cohort Study, 1997-2014. J Acquir Immune Defic Syndr 2019;80:145-51. [PMID: 30422912 DOI: 10.1097/QAI.0000000000001904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kalantari H, Bagherpour B, Tavakoli T, Khodadoostan M, Hejazi SM, Saadatmand A. The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin. J Res Med Sci 2019;24:12. [PMID: 30988680 DOI: 10.4103/jrms.JRMS_621_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Schuster Bruce C, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med 2019;16:e1002873. [PMID: 31504034 DOI: 10.1371/journal.pmed.1002873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
18 Abd Alla MDA, Elibiary SA, Wu GY, El-Awady MK. Occult HCV Infection (OCI) Diagnosis in Cirrhotic and Non-cirrhotic Naïve Patients by Intra-PBMC Nested Viral RNA PCR. J Clin Transl Hepatol 2017;5:319-26. [PMID: 29226098 DOI: 10.14218/JCTH.2017.00034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Lee S, Mailar K, Kim MI, Park M, Kim J, Min DH, Heo TH, Bae SK, Choi W, Lee C. Plant-Derived Purification, Chemical Synthesis, and In Vitro/In Vivo Evaluation of a Resveratrol Dimer, Viniferin, as an HCV Replication Inhibitor. Viruses 2019;11:E890. [PMID: 31547617 DOI: 10.3390/v11100890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tapper EB, Parikh ND, Green PK, Berry K, Waljee AK, Moon AM, Ioannou GN. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clin Gastroenterol Hepatol 2020;18:1197-1206.e7. [PMID: 31589975 DOI: 10.1016/j.cgh.2019.09.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]